SAB BIO receives FDA clearance for new diabetes treatment, appoints new CFO, and establishes advisory board

From GlobeNewswire: 2024-08-08 17:51:00

SAB BIO (Nasdaq: SABS) received FDA clearance for IND application for SAB-142 to treat type 1 diabetes. Lucy To appointed CFO, joining from Wells Fargo Securities. Establishment of Clinical Advisory Board for therapeutic development also announced. Financial results show $37.3 million in cash as of June 30, 2024, enough to fund operations until 2026.



Read more at GlobeNewswire:: SAB BIO Announces Second Quarter 2024 Financial Results and